Globus Medical Inc. (NYSE:GMED): A GARP Stock with Strong Growth and a Reasonable Valuation

For investors looking for a mix of chance and caution, the "Growth at a Reasonable Price" (GARP) method presents a solid middle path. It seeks to find companies with good and lasting expansion, but whose stock prices are not at the high levels common to popular momentum shares. This method usually looks for businesses with sound basics, including good financials and steady earnings, to back their expansion path, making sure the investment rests on a firm base instead of uncertain excitement. One stock that recently appeared through such a value-oriented growth filter is Globus Medical Inc - A (NYSE:GMED).

A Look at the Basic Profile

A check of the detailed basic analysis report for Globus Medical shows a total score of 6 out of 10. This rating, measured against 187 similar companies in the Health Care Equipment & Supplies field, describes a firm with clear positives that fit the value-oriented growth idea. The report separates performance into five key parts: Growth, Valuation, Health, Profitability, and Dividend.

Growth: Good Past Speed with a Firm View

The central idea of any growth plan is, expectedly, growth. Globus Medical does well here, getting a Growth score of 7. The firm has shown notable enlargement, especially in its sales and profits.

• Sales Growth: Over the last year, sales rose by 11.75%. More notably, the average yearly sales growth over recent years is a solid 26.25%.
• Earnings Per Share (EPS) Growth: EPS increased by 22.76% in the past year, with a good 13.19% average yearly growth rate over a longer time.
• Coming Estimates: Experts predict continued growth, with EPS expected to rise by 10.62% each year and sales by 8.32% on average in the future.

While the coming growth rate is thought to slow from its outstanding past speed, it stays quite good. This shown skill to grow with profit is just what GARP investors want—a history of results that gives trust in future estimates.

Valuation: Fair Inside a Costly Field

A fair price is what divides "value-oriented growth" from paying too much for possibility. Globus Medical's Valuation score of 6 shows it is not overly costly, particularly within its field setting. The study gives a varied but finally positive image.

• P/E Ratios: The company's Price/Earnings (P/E) ratio of 24.35 and Forward P/E of 20.64 match the wider S&P 500 average. More significantly, when compared to its own field—where average P/E ratios are much higher—GMED looks relatively inexpensive. It is priced lower than about 77% to 80% of its field rivals on these measures.
• Other Price Measures: The argument gets stronger when checking other metrics. Based on its Enterprise Value to EBITDA and Price/Free Cash Flow ratios, GMED is priced more cheaply than over 81% and 88% of its field competitors, in order.

For a GARP plan, this is a main point. Investors are not paying extra for the field; they are getting a growing company at a price that gives a buffer compared to its sector.

Supporting Basics: Health and Profitability

Lasting growth cannot happen without a firm financial structure. This is where Globus Medical's Health and Profitability scores, both at 7, support the investment case.

• Financial Health: The firm shows very good stability, with an Altman-Z score of 11.80, pointing to very little short-term failure risk and doing better than over 90% of the field. It has no debt, leading to a Debt/Equity ratio of 0.00, and has good cash availability with a Current Ratio of 4.13. This strong balance sheet gives steadiness and option to handle economic changes and put money into future expansion.
• Profitability: GMED creates high-grade profits. Its Return on Assets (8.32%), Return on Equity (9.63%), and Return on Invested Capital (8.29%) all sit in the top part of its field. Also, its Profit Margin of 15.30% and Operating Margin of 17.37% are better than most peers. Good profitability is needed to fund internal growth and create investor returns without too much need for outside money.

Summary

Globus Medical shows a solid outline for investors using a value-oriented growth plan. The company pairs good past and expected future growth with a price that is fair, notably within its high-multiple field. This possibility is supported by very good financial health and better-than-average profitability, which lower danger and help the lasting nature of its expansion path. While the stock does not give a dividend, it puts its cash back into the business, which is common and often wanted for growth-focused companies.

The value-oriented growth filter that found GMED is made to find more chances like this. If you want to find other stocks that mix growth, price, and sound basics, you can view the full filter findings here.

---

Disclaimer: This article is for information only and is not financial guidance, a suggestion, or a bid to buy or sell any securities. The information given is based on supplied data and should not be the only reason for any investment choice. Investing has risk, including the chance to lose the original amount. You should do your own study and talk with a certified financial consultant before making any investment choices.